Page 29 - pesta2013_3

1 3
l Powerful performance in HIV -

lntroducing - the first
STR with an integrase inhibitor and

Truvada backboneH

lndlcatlon: &TW.I!t .D. Is lndieated • Highly effective -robust vlrologic response comparable
for th& treatment of human to two guideline·preferred regimcns'·'
inwnunodefici&ncy virus- l (HIV· l)
infection in aduts aged 18 yeats - 90% of subjecls tak.ing STA IS ILD reached undetectable
and ()'(f!l who are antretroviral virat loads compa.red to 8 7% of subjects taking
trealment-na'rve ot ate i"!fected ATV+RTV + FTCITDF at 48 weeks
with HIV· l with001 k.nown mtAations
a~vd wilh r~ance to MY - 88% of subjects taking StlllbiL.D reaclled undetectable
of 1~ throo anliirotrovifalt1,9onls viral loads compared to 8 4% of subjects taking
in TRtltiL EFV/FTCITDF al 48 weeks
• Good tolerability - the toterability profile you have come to
expect from the integrase inhibitor c.rass'. as demonstrated
by the low discontinuation rate <4% aeross both studies'.t
• Very convenient - one tablet once daily
to assist adherence•

Rethink Performance